R&D News | pharmaphorum

News

Novartis has started construction of a $1.1bn biomedical research centre in San Diego that will serve as the hub for its R&D operations.

News

Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D with a $350m upfront payment.

News

Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic stroke by 26%, according to the OCEANIC-STROKE trial.

News

Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly asthma drug.

News

Eikon and Veradermics push upsized IPOs over the line, as Salspera, which is developing live microbial immunotherapies for cancer, seeks a listing.

News

Novo Nordisk is considering filing CagriSema for diabetes, in addition to obesity, after it outperformed Ozempic in a head-to-head study.